Comparative Pharmacology
Head-to-head clinical analysis: TRI SPRINTEC versus VOLNEA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRI SPRINTEC versus VOLNEA.
TRI-SPRINTEC vs VOLNEA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and norgestimate suppresses gonadotropin release, inhibiting ovulation, and increases viscosity of cervical mucus to inhibit sperm penetration.
Volnea is a combination of dienogest and ethinylestradiol. Dienogest is a progestin with antiandrogenic activity, and ethinylestradiol is an estrogen. The contraceptive effect is achieved through suppression of gonadotropins (FSH and LH), inhibition of ovulation, and changes in cervical mucus and endometrium.
One tablet (0.035 mg ethinyl estradiol / 0.250 mg norgestimate) orally once daily for 21 days, followed by 7 days of placebo tablets. Repeat cycle.
One tablet (0.02 mg ethinylestradiol + 3 mg drospirenone) orally once daily for 21 consecutive days, followed by a 7-day hormone-free interval.
None Documented
None Documented
Norelgestromin: 28 hours; Ethinyl estradiol: 17 hours. Steady-state achieved within 7 days.
Terminal half-life: 12 hours (range 10-14 h). Supports twice-daily dosing in patients with normal renal function.
Renal: 50% (metabolites); Fecal: 35% (eliminated in bile); unchanged drug <1%.
Renal: 70% unchanged; fecal: 30% (biliary elimination)
Category C
Category C
Oral Contraceptive
Oral Contraceptive